SpringWorks Releases Long-Term Efficacy and Safety Results from DeFi Trial of Ogsiveo

Long-term Efficacy of Ogsiveo: SpringWorks Therapeutics published long-term data from the Phase 3 DeFi trial in the Journal of Clinical Oncology, showing that Ogsiveo significantly reduced tumor size and improved objective response rates in adults with progressing desmoid tumors over extended treatment periods.

Patient-Reported Outcomes: The study indicated sustained improvements in patient-reported outcomes related to pain, symptom severity, and quality of life, with benefits observed early and maintained through up to 45 months of treatment.

Safety Profile: The safety profile of Ogsiveo remained consistent, with a decrease in the incidence and severity of treatment-emergent adverse events over time, despite common side effects such as diarrhea and fatigue.

Data Cutoff and Treatment Duration: The analysis utilized a December 2024 data cutoff, with a median treatment duration of 33.6 months, highlighting the progressive improvement in objective response rates from 34.3% in the first year to 45.7% for patients treated for up to four years.